US clinical-stage oncology drug developer MabVax Therapeutics (OTCQB: TELK) has granted to Denmark-based Y-mAbs Therapeutics an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric cancer.
News of the deal sent the US firm’s shares up 7.6 to $0.58 by mid-morning trading today.
A third of neuroblastoma patients are diagnosed as infants; and 90% are younger than five years of age at time of diagnosis. Neuroblastoma is responsible for 12% of all cancer deaths in children less than 15 years of age.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze